Replies to post #11957 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I note the funding of clinical expenses vis. AD ind and bearing of all sales and marketing expense as well as the royalties that I assume are above and beyond the OA scope of this deal.<

That’s correct—the $257M figure does not include Ovation’s development expenses, payments to GTC for manufactured product, or royalties on commercial sales.